Preclinical development of a GM-CSFR antibody

British Journal of Pharmacology

Volumn 168, Issue 1, 2013, Pages 200-211

  Minter, R R ^a   Cohen, E S ^a   Wang, B ^a   Liang, M ^a   Vainshtein, I ^a   Rees, G ^a   Eghobamien, L ^a   Harrison, P ^a   Sims, D A ^a   Matthews, C ^a   Wilkinson, T ^a   Monk, P ^b   Drinkwater, C ^c   Fabri, L ^c   Nash, A ^c   McCourt, M ^a   Jermutus, L ^a   Roskos, L ^a   Anderson, I K ^a   Sleeman, M A ^a  

^a MEDIMMUNE   (United States)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c CSL LIMITED   (Australia)

Author keywords

affinity maturation; GM CSFR; phage display; rheumatoid arthritis; scFv

Indexed keywords

574 D 04; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR ALPHA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR ALPHA ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN;

ADULT ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; COMBINATORIAL PHAGE DISPLAY; COMPUTER MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MOUSE; NONHUMAN; PHAGE DISPLAY; PREDICTION; PRIORITY JOURNAL; PROTEIN ENGINEERING; RECEPTOR OCCUPANCY; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; ANIMAL; BIOLOGICAL MODEL; CELL SURFACE DISPLAY; DRUG ANTAGONISM; HUMAN; IC 50; IMMUNOLOGY; METABOLISM; PROTEIN BINDING;

ANIMALS; ANTIBODIES; ARTHRITIS, RHEUMATOID; CELL SURFACE DISPLAY TECHNIQUES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INHIBITORY CONCENTRATION 50; MACACA FASCICULARIS; MALE; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RECOMBINANT PROTEINS;

EID: 84872839818     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02173.x     Document Type: Article

References (36)

1. Arunlakshana O, Schild HO, (1959). Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14: 48-58.
2. Baker KP, Edwards BM, Main SH, Chol GH, Wager RE, Halpern WG, et al. (2003). Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48: 3253-3265.
3. Barbas CF, Hu D, Dunlop N, Sawyer L, Cababa D, Hendry RM, et al. (1994). In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A 91: 3809-3813.
4. Bell AL, Magill MK, McKane WR, Kirk F, Irvine AE, (1995). Measurement of colony-stimulating factors in synovial fluid: potential clinical value. Rheumatol Int 14: 177-182.
5. Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F, (2011). Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 70: 1542-1549.
6. Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA, (2001). Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res 3: 293-298.
7. Farahat MN, Yanni G, Poston R, Panayi GS, (1993). Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 52: 870-875.
8. Feldmann M, Brennan FM, Maini RN, (1996). Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397-440.
9. Hawkins RE, Russell SJ, Winter G, (1992). Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 226: 889-896.
10. Hercus TR, Bagley CJ, Cambareri B, Dottore M, Woodcok JM, Vadas MA, et al. (1994). Specific human granulocyte-macrophage colony-stimulating factor antagonists. Proc Natl Acad Sci U S A 91: 5838-5842.
11. Kabat EA, (1991). Sequences of Proteins of Immunological Interest, 5th edn. NIH publication; no. 91-3242. U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health: Bethesda, MD.
12. Kenakin TP, (1982). The Schild regression in the process of receptor classification. Can J Physiol Pharmacol 60: 249-265.
13. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
14. Langmuir I, (1916). The constitution and fundamental properties of solids and liquids. Part I Solids. J Am Chem Soc 38: 2221-2295.
15. McCafferty J, Fitzgerald KJ, Earnshaw J, Chiswell DJ, Link J, Smith R, et al. (1994). Selection and rapid purification of murine antibody fragments that bind a transition-state analog by phage display. Appl Biochem Biotechnol 47: 157-171. discussion 171-173.
16. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reportingexperiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
17. Metcalf D, Nicola NA, Mifsud S, Di Rago L, (1999). Receptor clearance obscures the magnitude of granulocyte-macrophage colony-stimulating factor responses in mice to endotoxin or local infections. Blood 93: 1579-1585.
18. Mikuls TR, Fay BT, Michaud K, Sayles H, Thiele GM, Caplain L, et al. (2011). Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford) 50: 101-109.
19. Mizushima S, Nagata S, (1990). pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 18: 5322.
20. Nicola NA, Peterson L, Hilton DJ, Metcalf D, (1988). Cellular processing of murine colony-stimulating factor (Multi-CSF, GM-CSF, G-CSF) receptors by normal hemopoietic cells and cell lines. Growth Factors 1: 41-49.
21. Ottonello L, Cutolo M, Frumento G, Arduino N, Bertolotto M, Manchini M, et al. (2002). Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology (Oxford) 41: 1249-1260.
22. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. (2010). Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70: 588-597.
23. Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom HR, (1997). An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 187: 9-18.
24. Plater-Zyberk C, Joosten LA, Helsen MM, Hepp J, Baeuerle PA, Van Den Berg WB, (2007). GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis 66: 452-457.
25. Roskos L, Davis C, Schwab G, (2004). The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res 61: 108-120.
26. Sabroe I, Hartnell A, Jopling LA, Bel S, Ponath PD, Pease JE, et al. (1999). Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. J Immunol 162: 2946-2955.
27. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, et al. (1996). Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 263: 551-567.
28. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. (2009). Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev (4) CD007848.
29. Symmons DP, (2002). Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 16: 707-722.
30. Taylor PC, Feldmann M, (2009). Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5: 578-582.
31. Thom G, Cockroft AC, Buchanan AG, Candotti CJ, Cohen ES, Lowne D, et al. (2006). Probing a protein-protein interaction by in vitro evolution. Proc Natl Acad Sci U S A 103: 7619-7624.
32. Thompson J, Pope T, Tung JS, Chan C, Hollis G, Mark G, et al. (1996). Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. J Mol Biol 256: 77-88.
33. Vaughan TJ, Williams AJ, Prichard K, Osbourn JK, Pope AR, Earnshaw JC, et al. (1996). Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14: 309-314.
34. Walker F, Burgess AW, (1987). Internalisation and recycling of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on a murine myelomonocytic leukemia. J Cell Physiol 130: 255-261.
35. Wiley HS, Herbst JJ, Walsh BJ, Lauffenburger DA, Rosenfeld MG, Gill GN, et al. (1991). The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J Biol Chem 266: 11083-11094.
36. Yang WP, Green K, Pinz-Sweeney S, Briones AT, Burton DR, Barbas CF, 3rd (1995). CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 254: 392-403.